PFE Stock - is Pfizer's Stock a Good Buy for 2019? $PFE | Summary and Q&A

TL;DR

Analyzing Pfizer's stock performance, financial projections, and market strategy for potential investments.

Key Insights

• 💪 Pfizer showed strong stock performance in 2018 with a 25% gain.
• 👨‍💼 Strategic shifts in business focus and restructuring efforts aim to drive growth.
• 📡 The joint venture with GlaxoSmithKline signals a move towards efficiency and revenue generation.

Transcript

hey YouTube I'm Jimmy in this video I'm gonna walk through my analysis of Pfizer ticker symbol PFE this is the 22nd video in our series where we're analyzing all 30 stocks in the Dow Jones Industrial Average we're then going to take that analysis and build three different portfolios a dividend a value and a growth portfolio Pfizer is a global pharm... Read More

Questions & Answers

Q: How has Pfizer's stock performance been in 2018?

Pfizer saw a strong 25% gain in stock returns in 2018, outperforming the market.

Q: What are Pfizer's key strategies for future growth?

Pfizer's new CEO is focusing on specialty medicines, seeking profitable acquisitions, and restructuring for improved efficiency.

Q: What recent joint venture did Pfizer announce?

Pfizer announced a joint venture with GlaxoSmithKline to form a new company focused on consumer healthcare products, expected to generate income annually.

Q: How does the dividend discount model value Pfizer stock?

The dividend discount model estimates Pfizer's fair value at $58 per share, indicating potential undervaluation.

Summary & Key Takeaways

• Pfizer is a global pharmaceutical company with a diverse product portfolio.

• Strong performance in 2018 with a 25% gain in stock returns.

• Financial projections show expected growth in net income due to strategic shifts in business focus.